Thermo Fisher Scientific

Your educational resource for biopharma, pharma, environmental, food and agriculture, industrial, and clinical labs

  • Categories
    • Advancing Materials
    • Advancing Mining
    • AnalyteGuru
    • Analyzing Metals
    • Ask a Scientist
    • Behind the Bench
    • Biotech at Scale
    • Clinical Conversations
    • Examining Food
    • Identifying Threats
    • Illuminating Semiconductors
    • Life in Atomic Resolution
    • Life in the Lab
    • OEMpowered
    • The Connected Lab
  • About Us
  • Contact
Accelerating ScienceAnalyteGuru / Biopharmaceutical / Revolutionizing Host Cell Protein Detection and mAb Analysis in Biopharmaceuticals

Revolutionizing Host Cell Protein Detection and mAb Analysis in Biopharmaceuticals

By Lizzie Gallagher, Market Development Manager, Pharma and BioPharma, Thermo Fisher Scientific 09.22.2023

The Orbitrap Astral Mass Spectrometer and host cell proteins

Recombinant biotherapeutics have transformed medicine, but the presence of host cell proteins (HCPs) poses a risk to their safety and efficacy. Purification methods struggle to effectively remove residual HCPs, which can compromise the integrity of these vital drugs. However, the Thermo Scientific Orbitrap Astral Mass Spectrometer offers a solution, revolutionizing HCP detection and monoclonal antibody (mAb) analysis. Want to see how this achieved? Download our conference posters here.

Instrument schematic of the Thermo Scientific Orbitrap Astral Mass Spectrometer.

Traditionally, assessing the impact of individual HCPs on immunogenic relevance and product stability has been challenging. Liquid chromatography-mass spectrometry (LC-MS) emerged as a valuable tool, providing a broader view than ELISA. However, the dynamic range between HCPs and the drug product made detecting low concentrations difficult.

The Orbitrap Astral Mass Spectrometer takes HCP detection to a new level. With unparalleled sensitivity, it identifies HCPs at sub-ppm levels, ensuring the utmost safety and efficacy of biotherapeutic drugs. Check out our poster in which we demonstrate how you can achieve clear identification of HCPs at sub-ppm level with increased throughput.

The Orbitrap Astral Mass Spectrometer and monoclonal antibodies

This ground-breaking instrument enables scientists to achieve comprehensive mAb analysis across diverse modalities on a single platform with exceptional throughput.

The Orbitrap Astral Mass Spectrometer’s high-resolution accurate-mass analyzer sets it apart. Its unique workflow captures ions during the initial MS1 Orbitrap analysis, trapping and fragmenting them at remarkable speeds. This high-throughput analysis maintains precision.

Harnessing the power of asymmetric ion mirrors and ion foil, the Orbitrap Astral Mass Spectrometer achieves up to 80,000 resolution. This exceptional clarity enables scientists to analyze complex mAb samples and detect even subtle molecular variations. The ion foil shapes and focuses ions, enhancing resolution and sensitivity, crucial for most in-depth and accurate understanding of mAb composition.

The Orbitrap Astral Mass Spectrometer consolidates various analytical techniques into a single platform, streamlining workflows and expediting mAb characterization. From peptide mapping to native intact mass analysis, researchers can efficiently analyze a large number of samples, facilitating faster research and development in the biopharmaceutical industry.

Ready to unlock the potential of the Orbitrap Astral Mass Spectrometer?

Download our posters now to explore the possibilities and discover how this ground-breaking instrument can transform HCP detection and mAb analysis. Click here to access the posters and revolutionize your research.

Related information

Blog 2: Poster Series: A Journey into the World of Biopharma Column Chemistry
Blog 3: Take a Step Closer to Unlocking Full Potential of AAV Gene Therapy – Download the Poster
Blog 4: Unlocking the Future of Medicine: Exploring Therapeutic Oligonucleotides
Blog 5: Unveiling Hidden Impurities: LC-HRMS for Biopharmaceutical Analysis

On LinkedIn? Visit our LinkedIn page #biopharmaceuticals

Excedion Pro Banner

Discover. Innovate. Exceed. — Introducing the Thermo Scientific Orbitrap Excedion Pro Mass Spectrometer

Mass spectrometry is entering a new era of precision, perfor...

Read More
Innovation in Biopharma analysis image

Scaling Up Biopharmaceutical Characterization with the Orbitrap Ascend BioPharma Tribrid Mass Spectrometer

Biopharmaceutical pipelines are expanding rapidly, with incr...

Read More
Imaging Large Multiprotein Complexes Using Native Nano DESI Mass Spectrometry

Imaging Large Multiprotein Complexes Using Native Nano DESI Mass Spectrometry

Prof. Helen Cooper, Ph.D., an expert analytical chemist from...

Read More
celebrating with whisky

The Spirit of Christmas: Ensuring the Quality and Authenticity of Whisky

It’s Christmas! Again! A time of year to celebrate and ref...

Read More

Lizzie Gallagher

Lizzie Gallagher is a market development manager for the pharma and biopharma market at Thermo Fisher Science, having spent a number of years in both industry, and sales and marketing. Lizzie has widespread experience with the challenges and trends of the biopharma and pharma market.
How This Lab Improves Enzyme Standardization for Outstanding Food Production
4 Ways to Increase Your GC Lab’s Efficiency

Privacy StatementTerms & ConditionsLocationsSitemap

© 2025 Thermo Fisher Scientific. All Rights Reserved.

Talk to us